Parallel Bio
New accelerator entry · 2021-07-20 · the record
In their words
Parallel Bio is pioneering human-first drug discovery by creating the first map of human biology. Using groundbreaking biological and computational tools that track real clinical outcomes, the company generates data that enable earlier, more reliable decisions about disease biology and drug development. Parallel Bio’s platform overcomes the core limitations of traditional animal testing, which fails to encapsulate the complexity of human biology. The company is building internal pipelines of novel disease targets and drug candidates in both cancer and autoimmune disease, while collaborating with pharmaceutical companies to evaluate therapies directly in human systems to reduce the cost and risk of clinical trials. Based in San Francisco, the company was founded in 2021 by two of the world’s leading experts in replacing animal models with human-first platforms.
What the record says
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Parallel Bio
- Source Check — verify what Parallel Bio states, against the registers that hold it.
- INVEST — size up this company on the figures its record states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Parallel Bio for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Parallel BioYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Parallel Bio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.